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ABSTRACT 
Lung cancer is the leading cause of all cancer deaths in men and women 
combined, killing more than 150,000 patients per year. Lymph node status is the 
best predictor of survival in patients with surgically resectable lung cancer. The 5 
year survival rates for node negative (N0), hilar node positive (N1), and 
mediastinal node positive (N2) disease is 53.8%, 26.3%, and 20.8%, 
respectively. Accurate staging of the disease will lead to the most effective 
adjuvant therapy strategy. However, routine pathologic analysis of sampled 
lymph nodes underestimates the prevalence of metastatic disease. Patients with 
missed metastatic disease do not receive proper treatment which likely 
contributes to the high recurrence rate and poor 5 year survival of lung cancer 
patients. Detection of lymph nodes at highest risk for harboring metastatic 
disease (i.e. sentinel lymph nodes (SLN)) may permit more intensive histologic 
analysis to detect occult disease. Presently there is no safe and reliable method 
for detecting SLNs. The overall objective of this project was to identify the SLNs 
and treat them. 
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To do this, we looked at the feasibility of using indocyanine green (ICG) and near 
infrared (NIR) imaging in a minimally invasive video assisted thoracic surgery 
procedure to identify the SLNs in patients with suspected Stage I/II non small cell 
lung cancer (NSCLC). Previous attempts at SLN identification in patients with 
NSCLC using radioisotopes and blue dyes have been ineffective. ICG and NIR 
imaging for identification of SLNs has become standard of care in both 
melanoma and breast cancer. We looked to extend this technology to NSCLC. 
Patients were given an intraparenchymal, peritumoral injection of ICG and 
imaged with a NIR camera noting lymphatic migration, time to SLN identification, 
number of SLNs, and lymph node station. Our results demonstrated the 
increased rate of SLN identification over the previous studies. 
  
Having demonstrated the feasibility of ICG and NIR imaging for SLN identification 
in patients with NSCLC, we looked to treat these high risk nodes. Treatment of 
metastatic disease without having to perform a lymphadenectomy would allow 
the surgeon to leave the lymphatic system of the lung intact, thusly avoiding 
associated morbidities of a lymphadenectomy procedure. Recent studies have 
demonstrated the effectiveness of intralymphatic drug delivery at increasing the 
concentration of drug within the lymph nodes. Additionally, expansile 
nanoparticles (eNP) loaded with a chemotherapeutic agent (paclitaxel) have 
been shown to migrate through the lymphatics in the intestine of a large animal 
and localize in the lymph nodes. We looked to extend these observations to 
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thoracic malignancies. To do this, we injected rhodamine labeled eNPs (Rho-
eNP) into the chest cavity of tumor burdened athymic mice to look for lymphatic 
migration of the Rho-eNPs to the mediastinal lymph nodes. Our results 
demonstrated the lymphatic migration of the Rho-eNPs towards the mediastinal 
lymph nodes. This would suggest that it is feasible for an injection of eNPs into 
the lungs of patients with lung cancer to migrate through the lymphatics to the 
lymph nodes.  
 
Targeted lymphatic delivery of drug by eNPs to SLNs identified by ICG and NIR 
imaging opens up treatment options for patients with lung cancer. Leaving the 
lymphatic system intact while still effectively treating metastatic disease may help 
to reduce recurrence rates and improve on the 5 year survival rates of patients 
with lung cancer. 
 vi 
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1.  INTRODUCTION 
More people die from lung cancer than any other type of cancer. It has a death 
rate of nearly 51 per 100,000 men and women per year1. In surgically resectable 
disease, the tumor may be removed by either a wedge resection, 
segmentectomy, lobectomy, or a pneumonectomy. In addition to removing the 
primary tumor, the surgeon will perform a lymphadenectomy to evaluate the 
regional lymph nodes to check for nodal involvement. The sampled lymph nodes 
are examined by routine pathologic analysis to check for the presence of 
metastatic disease. The regional lymph node status is critical as it aids in the 
staging of the disease and in turn, devising more effective adjuvant therapy 
strategies. Based on statistics evaluated from the population-based Surveillance, 
Epidemiology and End Results database from 1990 to 2000, lymph node status 
is the most important indicator for survival in patients with lung cancer2. However, 
routine pathologic analysis of the lymph nodes underestimates the prevalence of 
occult disease. When sampled lymph nodes are analyzed retrospectively by 
immunohistochemistry (IHC), micrometastatic disease has been shown in about 
16% of patients with early node negative lung cancer and up to 27.5% of patients 
with subcentimeter adenocarcinomas3,4. However, performing IHC on each 
lymph node removed in a lymphadenectomy specimen is too costly and thus, not 
a practical option. This gross understaging of the disease leads to 
undertreatment of the disease and thus a higher chance for recurrence. In 
patients with Stage I disease (i.e. no regional lymph node or distant metastases) 
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with a “complete surgical resection”, recurrence rates range from 25-50%5. The 
overall objective of this project was to find the lymph nodes at greatest risk for 
harboring metastatic disease in patients with lung cancer, and treat them.  
 
In treatment of patients with lymph nodes positive for metastatic disease, the 
goal is to deliver as much chemotherapy to the lymph nodes as possible so as to 
destroy all tumor cells while avoiding systemic toxicity and damage to nearby 
healthy tissues. The current standard procedure for chemotherapy treatment in 
lung cancer employs the use of an intravenous delivery method. However, there 
are limitations to the amount of drug that can be administered due to the risk of 
systemic toxicity. Further drug may also be cleared by the liver and kidneys. With 
a dose limitation and drug being cleared from the body, the amount of drug that 
actually makes it to the positive, or metastatic, lymph nodes is limited and thus 
the desired effect is suboptimal. 
 
A method of intraoperatively analyzing the lymphatic drainage pattern of primary 
lung cancer tumors that allows surgeons to accurately and consistently be able to 
identify the lymph nodes at highest risk for harboring metastatic disease (i.e. the 
sentinel lymph node (SLN)) would allow the surgeons to more accurately stage 
the disease, in turn leading to better options for treatment. A drug delivery 
system that could use the lymphatic drainage pattern of the primary tumor for 
targeted drug delivery to the SLN would allow the surgeon the ability to prevent 
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and/or attack the metastatic disease without having to perform a 
lymphadenectomy. This in turn would leave the lymphatic system of the lung 
uninterrupted, thereby avoiding any associated morbidities of a 
lymphadenectomy procedure, such as prolonged air leak.  
 
This thesis focuses on investigating the feasibility of near infrared (NIR) imaging 
as a means of identifying the lymphatic drainage pattern of a primary tumor to the 
SLN in patients with non-small cell lung cancer (NSCLC). It also investigates the 
intrathoracic lymphatic delivery of expansile nanoparticles (eNP) to the targeted 
lymph node for use in lymphatic drug delivery in patients with thoracic 
malignancies.  
 
2.  BACKGROUND 
 
2.1  Cancer and metastasis 
Cancer is the unregulated growth of tissues. Malignant tumors are collectively 
referred to as cancers. All tumors are composed of two basic components, a 
parenchyma and a stroma. The parenchyma largely determines the biologic 
behavior of the tumor, and is composed of transformed or neoplastic cells6. The 
stroma is composed of connective tissue, blood vessels, and host-derived 
inflammatory cells. The stroma is crucial to the growth of the tumor as it provides 
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support for the growing parenchyma and carries the blood supply, thusly 
providing a means for metastasis6.  
 
A primary tumor will grow as large as can be supported by the regional blood 
flow, which supplies the tumor cells with oxygen and nutrients. In order for the 
primary tumor to continue growing, more oxygen and nutrients must be delivered 
to the tumor cells to support growth and cell health. Recent investigations have 
demonstrated a consistent link between hypoxia and tumor invasion and 
metastasis. Hypoxia produces expression of Hypoxia Induced Factor-1(HIF-1). 
Increased expression of HIF-1 has been shown in numerous solid malignant 
tumor types, including lung cancer. In 2007, López-Lázaro demonstrated that 
HIF-1 regulates the expression of numerous molecules that are critical mediators 
of cell adhesion and migration, such a matrix metalloproteinases (MMP)7. MMPs 
degrade the extracellular matrix thereby making it easier for tumor cells that have 
broken off from the primary tumor to migrate from the primary tumor site to a 
distant site, such as lymph vessels. Additionally, HIF-1 has been shown to 
repress cadherins, molecules that have a critical role in cell-cell adhesion7. 
Repression of these molecules would facilitate the entry of tumor cells into the 
lymph vessels where they may then be transported throughout the body to 
establish a new tumor site, such as lymph nodes.  
 
Tumors may metastasize by one of three pathways, all beginning with tumors 
cells breaking off from the primary tumor. The first pathway is seeding within 
 5 
body cavities, in which the free tumor cells invade a natural body cavity. The 
second is hematogenous spread, in which the free tumor cells invade arteries 
and veins. Once inside the vascular system, they may be transported throughout 
the body to establish a new site in a distant organ or tissue and begin to grow. 
The last is lymphatic spread, in which the free tumor cells invade the lymphatic 
system. Once inside the lymphatic system, tumor cells can migrate throughout 
the body, often establishing new sites in the lymph nodes6. Tumor metastasis via 
the lymphatic system is accomplished through either spread by pre-existing 
lymphatic vessels in the vicinity of the primary tumor, or by lymphangiogenesis. 
In spreading by pre-existing lymphatic vessels, Achen et al. showed that entry of 
tumor cells into the lymphatic system is facilitated by the thin walls and 
incomplete basement membrane of the lymphatic vessels which does not provide 
a significant barrier8. Additionally, tumor-associated antigens, shed by tumor cells 
or released by cell death, along with the disseminated tumor cells, may be picked 
up in the lymph and carried to the draining lymph nodes9. The regional lymph 
nodes are important as they are often the first site to encounter the disseminated 
tumor cells in the draining lymph and are thusly, often the first site of metastatic 
disease. 
 
2.2  Mechanisms of Lymphangiogenesis 
In spreading by lymphangiogenesis, tumor cells secrete growth factors that 
stimulate the growth of new lymphatic vessels towards the primary tumor. These 
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growth factors stimulate their corresponding receptor tyrosine kinase embedded 
within the cell membrane of the target cell, triggering a signaling cascade that 
leads to cell growth, migration, and survival. Multiple studies have shown that 
Vascular Endothelial Growth Factor (VEGF), a family of glycoproteins that 
stimulate Vascular Endothelial Growth Factor Receptors (VEGFR), a family of 
receptor tyrosine kinases located in endothelial cells, is expressed by a variety of 
solid malignant tumors, one such being NSCLC, to stimulate lymphangiogenesis. 
VEGF-C has been shown to promote squamos cell carcinoma, a type of NSCLC, 
metastasis to lymph nodes10. Endothelial cells exposed to the highest VEGF-C 
concentration become tip cells. Tip cells lead the developing sprout by extending 
numerous filopodia. The developing sprout elongates by proliferation of 
endothelial stalk cells that trail behind the tip cell (Figure 1). The tip cells continue 
to migrate towards the VEGF source until the stimulus is removed. Achen et al. 
showed that expression of VEGF-C and VEGF-D by tumor cells in animal models 
of cancer led to an increase in the number of lymphatic vessels around, and 
sometimes within the primary tumor, promoted spread of tumor cells to lymph  
                  
Figure 1. Mechanism of Lymphangiogenesis. Tumor cells (white) secrete VEGF-C (red), which 
stimulates growth of new lymphatic vessels towards the primary tumor, faciliating metastatic 
spread. The vessel sprouts are lead by tip cells migrating to the VEGF-C source, and elongate by 
proliferation of lymphatic endothelial stalk cells. Figure adapted from American Association for 
Cancer Research ©2012. 
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nodes, and facilitated distant organ metastasis when the growth factors activated 
their corresponding receptor, VEGFR-3, located on the lymphatic endothelium as 
shown in Figure 28,10. Binding of the glycoprotein ligand causes dimerization of 
the receptor which leads to self phosphorylation of tyrosine residues within the 
intracellular portion of the receptors. Upon dimerization, a signaling cascade (the 
MAP kinase pathway (raf-MEK-ERK)) is activated that influences endothelial cell  
 
Figure 2: Metastasis by lymphangiogenesis. Tumor expression of VEGF-C and -D promotes 
lymphangiogenesis at the primary tumor and within the SLN, leading to metastasis. Lymphatic 
endothelial derived chemokine CCL21 promotes migration of CCR7 bearing tumor cells, facilitating 
their entry into the lymphatic system. Figure adapted from reference 10. 
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growth, differentiation, apoptosis, and migration. In addition to VEGF-C and -D, 
VEGF-A may be expressed by tumor cells. VEGF-A is an angiogenic factor 
expressed in hypoxic regions of the tumor. VEGF-A stimulates VEGFR-1 and 2. 
VEGFR-2 is also located on the surface of lymphatic endothelium, thereby 
promoting lymphangiogenesis upon stimulation. Additional growth factors 
secreted by tumor cells for lymphangiogenesis include Platelet Derived Growth 
Factor-BB, Hepatocyte Growth Factor, and Neuropilin-2. Angiopoeitins (ANG) 
are ligands for TIE2 receptors. ANG1 positively regulates remodeling of blood 
vessels. ANG2 promotes blood vessel regression by blocking TIE2 activation 
which destabilizes vessel walls of mature vessels, thereby aiding entry of tumor 
cells into the vessels. Insulin-like Growth Factors (IGF) stimulate IGF receptors. 
Stimulation of IGF-1 receptor promotes expression of VEGF-C. Chemokines 
(CCL), when secreted by lymph vessels or lymph nodes, attract the movement of 
tumor cells expressing cognate chemokine receptors (CCR) toward these 
structures, such as CCL21 attracting CCR7, as shown in Figure 2
8,10. Once inside 
the lymphatic system, the tumor cells migrate with the lymph, passing through 
lymph nodes where they may either be destroyed by the host immune defenses 
or if the lymph nodes become overburdened with tumor cells, may establish a 
new site and begin to grow. Currently there is no effective method for 
intraoperatively identifying the lymph nodes at greatest risk for harboring 
metastatic disease in patients with lung cancer.  
 
 9 
2.3  Lymph nodes and immune surveillance 
The lymphatic system consists of groups of cells, tissues and organs that monitor 
internal fluid compartments, body surfaces and mount responses to potentially 
harmful substances. The lymphatic vessels, which begin as blind capillaries in 
loose connective tissue, remove substances and fluid from the extracellular 
spaces forming lymph, a filtrate of the interstitial fluid. The lymph passes from 
afferent vessels, through lymph nodes, into efferent vessels on its way to being 
returned to the vascular system. The lymph nodes, which are peripheral or 
secondary lymphoid organs where adaptive immune responses develop, are 
interspersed along the lymphatic vessels, acting to filter the lymph as it traverses 
through the lymphatics before being returned to the vascular system. An 
important function of the filter system of the lymph node is immune surveillance, 
removing potentially harmful pathogens such as tumor cells. Each lymph node is 
composed of supporting elements, parenchyma, and sinuses.  The supporting 
elements include the capsule, trabeculae, and reticular tissue. The capsule 
surrounds the node and, along with the trabeculae, is composed of dense 
connective tissue. The trabeculae form a gross framework, extending from the 
capsule into the node, as depicted in Figure 311. The reticular tissue, which 
consists of reticular cells, dendritic cells, macrophages, follicular dendritic cells, 
reticular fibers and ground substance produced by those cells, forms a fine 
supporting meshwork throughout the rest of the lymph node11.  
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Figure 3. Structure of a lymph node. a) This diagram shows the overall structure and general 
features of the lymph node. b) This is a micrograph of a lymph node prepared with an H&E stain 
showing the gross features of the lymph node. Figure adapted from reference 11. 
 
The parenchyma comprises the cortex and medulla. The cortex, or outer portion 
of the node, is composed of a reticular framework, dendritic cells, follicular 
dendritic cells, lymphocytes, macrophages, plasma cells, lymphatic sinuses and 
lymph channels11. The superficial (nodular) cortex is composed of primary and 
secondary lymphatic nodules. Lymphatic nodules are distinct concentrations of 
lymphocytes contained in a meshwork of reticular cells, the secondary nodules 
containing a germinal center which develops when a lymphocyte recognizes an 
antigen and returns to a primary nodule and undergoes proliferation and 
differentiation of B lymphocytes11. The deep (paracortex) cortex is between the 
medulla and superficial cortex, is the site of most T cells, and contains no 
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nodules. The medulla is the inner part of the node. It consists of chords of 
reticular cells, lymphocytes (mostly B cells), macrophages, dendritic and plasma 
cells, separated by sinuses. Between the chords is a meshwork of reticular cells 
and fibers creating a framework for the parenchyma11. 
 
The sinuses of the lymph nodes are lymphatic channels that have a continuous 
lining of endothelium where it borders the dense connective tissue of the capsule 
or trabeculae but is discontinuous where it faces the parenchyma. Macrophages, 
located in the parenchyma, often send pseudopods into the sinuses through 
these discontinuities11. The subcapsular sinus, located between the capsule and 
cortical lymphocytes, receives the draining lymph from the afferent vessels and is 
therefore often the first site of lymph node metastases. The trabecular sinus 
originates from the subcapsular sinus, extends through the cortex along the 
trabeculae, and drains into the medullary sinuses. The medullary sinuses 
converge at the hilum of the node and drain into the efferent vessels11. VEGF-C 
has been shown to expand these lymphatic channels, thereby facilitating the 
migration of tumor cells through the lymph nodes to establish distant metastatic 
sites throughout the body. 
 
For a patient with surgically resectable lung cancer, lymph node status is the best 
predictor for survival. The 5 year survival rates for node negative (N0), hilar node 
positive (N1), and mediastinal node positive (N2) disease is 53.8%, 26.3%, and  
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Figure 4. Regional lymph node stations for lung cancer staging. N0 disease means no regional 
lymph node involvement. N1 disease refers to the Hilar nodes, stations 10-14. N2 disease refers 
to the ipsilateral mediastinal and aortic nodes, stations 1-9. N3 disease refers to contralateral 
mediastinal or supraclavicular nodal involvement. Figure adapted from reference 13. 
 
20.8%, respectively12. It is important to correctly stage the disease to devise the 
most effective adjuvant therapy strategy (Figure 413). Identification of the first 
lymph node to drain a specific tumor, and thus the most likely to harbor 
metastatic disease, i.e. the sentinel lymph node (SLN), would permit the in-depth 
histologic scrutiny with the goal of detecting micrometastases and properly 
staging the disease. 
 
The reticular system of the lymph nodes is the first line of defense in preventing 
the metastasis of primary tumors through the lymphatic system. The fine 
supporting meshwork can capture tumor cells as they are transported in the 
lymph. Once captured, the cells of the reticular system can eliminate the tumor 
cell through phagocytosis. If, however, more tumor cells are captured within the 
 13 
meshwork than can be eliminated by the reticular cells, the tumor may establish 
a new site and begin to grow11. Accurate staging of the disease relies on 
identification of these metastatic lymph nodes, which in turn leads to the most 
effective therapy strategy. However, there currently exists a need for a better 
method of identifying these lymph nodes in patients with lung cancer.  
 
2. 4  Sentinel lymph node theory 
The sentinel lymph node is the first lymph node to receive draining lymphatic fluid 
from a nearby primary tumor. The SLN has the greatest probability of harboring 
metastatic disease and is thus important for staging the disease. The theory of 
the SLN relies on the fact that the stage of the SLN is indicative of the stage of all 
the lymph nodes in the region14. If the SLN is negative for micrometastases, all 
other regional lymph nodes should be negative for tumor as well. If the SLN is 
positive, a more extensive lymphadenectomy may be performed or adjuvant 
chemo or radiation therapy could be recommended in order to treat tumor that 
has spread. By removing a single unique lymph node instead of performing an 
extensive lymphadenectomy, it allows for more intensive immunohistochemical 
staining which increases the likelihood of detecting occult disease, and also 
decreases the morbidity associated with an extensive lymphadenectomy15. More 
accurate staging of the disease may allow for more effective adjuvant therapy 
strategies and a greater survival rate as those patients that can benefit from 
additional therapy are identified and treated. SLN biopsy is currently the standard 
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of care in treatment of both melanoma and breast cancer. The procedure evolved 
as a better understanding of the relationship between cancer and lymphatics 
evolved from the ancient Greeks to present day. 
 
The ancient Greeks first postulated that cancer was the local manifestation of a 
systemic disease16. In the 19th century, the Prussian physician Rudolph Carl 
Virchow theorized that lymph nodes filter particulate matter from lymph. This 
theory contradicted ancient Greek philosophy by implying that cancer could be 
cured at an early stage with adequate surgery16. This idea influenced the 
operation described by Halsted in 1894 of a radical mastectomy in which the 
surgeon removed the entire breast, muscles and axillary lymph nodes in 
treatment of breast cancer17. This radical procedure remained the standard of 
care until the late 1990’s14.  
 
The SLN concept was first described in a paper published in 1960 by Gould et al. 
on parotid gland carcinomas. The paper reported a case in which a primary 
tumor appeared histologically benign until a biopsy of a macroscopically normal 
appearing lymph node revealed metastatic spread. The paper went on to stress 
the usefulness of radical neck dissections given the risk of false negatives in 
pathologic examination14. In 1977, Cabañas et al. investigated the SLN concept 
in penile carcinomas using contrast enhanced SLN identification. They 
discovered that the biopsy of the contrast enhanced lymph node could indicate 
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the tumor status of the regional nodal basin14. Chiappa et al. also noted the 
presence of SLNs using lymphangiographic studies in studying the lymphatic 
drainage of testicular cancer16. However, the term “sentinel” lymph node was not 
coined until Weissbach and Boedefeld published their findings after examining 
the feasibility of a limited retroperitoneal lymph node dissection16. The modern 
idea of lymphatic mapping and the SLN biopsy was pioneered by Morton et al. in 
their work with metastatic melanoma published in 1992. Morton et al. developed 
a procedure using vital dyes that permits intraoperative identification of the SLN. 
This technique, with a high degree of accuracy, allows for identification of 
patients with early stage melanoma who have nodal metastases and would thus 
benefit from extensive lymphadenectomies18. The SLN concept has been 
validated by multiple studies pertaining to melanoma and breast cancer, and has 
recently been extended to other cancers such as those of the head and neck, 
lung, thyroid, gastrointestinal and urogenital tracts, and some neuroendocrine 
subtypes15. 
 
2.5  SLN in Lung Cancer 
There exists a need for better approaches in identifying and analyzing SLNs to 
detect occult disease in patients with NSCLC. More than 50% of patients with 
apparent node negative NSCLC will die of metastases within 5 years1. Chen et 
al. discovered occult disease using IHC in 63% of lymph nodes that were tumor 
negative by standard pathologic techniques and tumor presence was confirmed 
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by reverse transcriptase-polymerase chain reaction (RT-PCR)19. Secondly, Gu et 
al. and Kubuschok et al. found decreased survival in NSCLC patients with occult 
metastases detected via IHC19. Benlloch et al. showed that RT-PCR can detect 
the presence of micrometastases in lymph nodes with greater precision than 
current staging methods used for assessing tumor recurrence risk20. Therefore, 
using these techniques can improve staging of NSCLC and lead to better 
adjuvant therapy strategies, but such extensive techniques would not be practical 
for all nodes removed in an extensive lymphadenectomy as it is too costly. Use 
of lymphatic mapping to detect the SLN would allow implementation of these 
techniques which would lead to better staging, better treatment strategies, and 
improved survival rates. However, SLN identification by current lymphatic 
mapping techniques in NSCLC is still highly variable. As shown in Table 1, SLN 
identification rates using the radioactive tracer Technetium-99 range from 61.5-
82%. Use of non radioactive tracers such as isosulfan blue dye or indocyanine 
green (ICG) only produced a SLN identification rate ranging from 6-46%. 
However, the use of ICG as a tracer was given at greater doses than those 
utilized in the clinical trial discussed below as an attempt to physically stain the  
Table 1. Intraoperative SLN Mapping in NSCLC Patients 
Authors Year N Tracer % Success 
Little et al.21 1999 16 Isosulfan blue dye 46% 
Liptay et al.22 2000 45 Technetium-99 82% 
Sugi et al.23 2002 36 Indocyanine green 6% 
Rzyman et al.24 2006 110 Isosulfan blue dye 26% 
Liptay et al.25 2009 39 Technetium-99 61.5% 
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lymph nodes green. The variability between these studies is thought to result 
from anatomical variations or imaging technique restrictions. Both of these 
approaches are technically limited studies as there is high background signal 
making it hard to detect a positive signal and difficult to tell negative background 
from a faint positive signal (i.e. low sensitivity and specificity). However, it is clear 
that new imaging techniques are needed to achieve higher levels of specificity 
and sensitivity. One such proposed solution is the use of indocyanine green 
(ICG) with a near infrared (NIR) fluorescence imaging platform. 
 
2.6  Near Infrared Imaging 
The International Organization for Standardization divides infrared light into three 
spectral regions, near (0.78µm - 3µm), mid (3µm - 50 µm), and far (50µm - 1000 
µm). The unaided human eye can only detect light in the visible light range, 400-
700nm, making NIR light invisible. When tissues absorb light, there is a chance 
that fluorescent light will be emitted. This autofluorescence may limit the signal to 
background ratio (SBR)26. Figure 5 demonstrates the relationship between 
excitation and emission wavelengths and autofluorescence. The green 
autofluorescence is quite large when excited by blue light, resulting in a 
significant amount of background. The red autofluorescence is slightly reduced 
when excited with green light but still results in a significant amount of 
background. However, the NIR autofluorescence is nearly nonexistent resulting 
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Figure 5. Excitation/emission wavelengths and autofluorescence. A Nu/Nu athymic mouse 
imaged at 2 mW/cm2 fluence rate with matched emission wavelength window and camera 
sensitivity a) white light image of mouse viscera. Tissue autofluorescence imaged under various 
excitation/emission filter sets. Figure adapted from reference 26. 
 
in low background26. In the human body, the major absorbers of NIR light are 
water, lipids, oxyhemoglobin (oxyHb), and deoxyhemoglobin (deoxyHb). Within 
the NIR window, all major absorbers of NIR light have low values of absorption 
resulting in low autofluorescence, or background (Figure 6). ICG is a compound 
from an important class of organic fluorophores, the heptamethine cyanines 
(Figure 7). ICG absorbs and emits light within the NIR spectrum, absorbing at a 
wavelength of about 806nm and emitting light at a slightly longer wavelength of 
about 830nm. Use of this dye with NIR light results in a high SBR within the 
human body26. In 1959, ICG received Federal Drug Administration approval for 
use in intravenous indicator dilution studies such as cardiac dye-dilution study, 
liver function and blood flow determination, and ophthalmic angiography27. 
Urticaria and rare anaphylaxis (1:30,000 to 40,000) are the only known adverse  
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Figure 6. Autofluoresnce within NIR window.                Figure 7. Molecular structure of  
Amount of absorption of light for water lipids,                indocyanine green. Figure adapted form 
oxyhemoglobin, and deoxyhemoglobin for                     reference 26. 
corresponding wavelengths of light emitted.  
Figure adapted from reference 26. 
 
reactions to ICG, occurring at much higher ICG doses than used in the clinical 
trial discussed below27. NIR light also penetrates more deeply into tissue and can 
reportedly detect fluorescent dyes like ICG located at depths greater than 1cm 
within human tissues. Use of an invisible light with low absorption and high 
penetration in human tissue makes NIR light an ideal platform for patient in-vivo 
imaging. A surgical field can simultaneously be illuminated by NIR excitation light 
and visible light and appear unaltered to the operating surgeon. Using an 
imaging platform that can simultaneously image reflected visible light and NIR 
fluorescence and overlay the two images to produce a color image (Figure 8) 
would allow the surgeon to visualize the exogenously administered contrast 
agent while maintaining a view of surgical anatomy. Use of a NIR imaging 
platform also has increased safety over other intraoperative imaging techniques. 
NIR light is not radioactive and no radioactive tracers are used, therefore there is 
no unnecessary exposure to the surgeon, patient, or other operating room staff to 
radiation. Using ICG and NIR fluorescence imaging for intraoperative lymphatic 
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  A    B    C 
Figure 8. In-vivo NIR imaging. A) White light image of porcine lung as seen by the unaided eye B) 
Pure NIR image displaying injection site (Inj), lymphatic migration (arrow head), and SLNs (arrow 
and asterisk) C) The merged white light and NIR images. Figure adapted from reference 28. 
 
mapping would not only help stage the disease, but lead to a better 
understanding of tumor lymphatic drainage patterns which may then be 
manipulated for targeted therapy. 
 
2.7  Lymphatic drug delivery 
With a more established method for detecting the SLN and staging the disease, 
new methods for chemotherapy delivery can be developed to treat and/or 
prevent early metastasis of the primary tumor into the lymph node. In 2004, Chen 
et al. conducted a study looking at whether lymphatic delivery of chemotherapy 
could improve accumulation of the drug in regional lymph nodes over intravenous 
delivery methods. The study looked at drug concentrations in axillary lymph 
nodes after receiving either lymphatic or intravenous chemotherapy in patients 
with breast cancer and compared the results29. A total of 60 patients participated 
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in the study, 30 in each group. Each group received 20 mg of carboplatin, the 
lymphatic chemotherapy group via a subcutaneous, peritumoral injection of 4 mL 
of carboplatin-activated carbon suspension, and the intravenous chemotherapy 
group via aqueous carboplatin. Six patients from each group then had modified 
radical mastectomies performed at time points 1, 12, 24, 36, and 48 hours after 
injection. The results showed that the mean carboplatin concentration was 
significantly higher in the lymphatic chemotherapy patients at all time points as 
compared to the intravenous chemotherapy patients29.  The lymphatic 
chemotherapy group displayed 11.82 +/- 3.50, 23.58 +/- 7.34, 18.22 +/- 4.93, 
16.70 +/- 5.15 and 14.62 +/- 4.29 µg/g (means +/- SD), respectively, whereas 
those in the intravenous chemotherapy group were 0.06 +/- 0.02, 0.11 +/- 0.05, 
0.10 +/- 0.02, 0.05 +/- 0.02 and 0 µg/g, respectively29. This study showed that 
lymphatic delivery of chemotherapy is an effective strategy for increasing the 
drug concentration in the regional lymph nodes. Having shown the efficacy of 
lymphatic drug delivery, more effective and safer strategies for delivering the 
chemotherapy have begun to be explored. One area of active research has 
explored the use of nanoparticles. 
 
2.8  Expansile nanoparticles 
Nanoparticles and their medical applications are a current area of interest and 
research. Nanoparticles are small molecules that are comprised of polymers of 
organic, metallic, or semiconducting materials that can be engineered into 
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various compositions, shapes, and sizes depending on their target function30. 
One of the most important design features of the nanoparticle is the high surface 
area to volume ratio which allows for carriage of a large payload. Nanoparticle 
migration can occur through either passive or active targeting of tissues. As 
previously discussed, tumors possess lymphangiogenic properties that can alter 
lymphatic drainage and breakdown vessel walls which can lead to increased 
uptake and retention of nanoparticles. Additionally, the surface of nanoparticles 
can be further engineered to incorporate target specific ligands, peptides, and 
oligonucleotides to aid in migration to the specific target site30. A current area of 
nanoparticle research in medical applications is drug delivery methods. The 
nanoparticles are being investigated as a means of increasing drug solubility, 
targeting specific sites, increasing the concentration of the drug at the targeted 
site, and minimizing the side effects of dose limiting toxicities 31. Currently the 
poly lactic-glycolic acid (PLGA) particle is the prototypical design for the 
nanoparticle drug delivery method due to its availability and biocompatibility32. 
However, the PLGA nanoparticles have been shown to have a rapid release of 
more than half the encapsulant in 10-48 hours which may limit their 
effectiveness32. Thusly nanoparticle design is being explored to engineer a 
particle capable of drug release triggered by specific stimuli such as pH, 
temperature, light, and ultrasound 32. In a study published in 2009, Griset et al. 
demonstrated the ability of engineered pH-responsive methacrylate nanoparticles 
to swell upon uptake within the endosome of a tumor cell, and release the 
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chemotherapy payload. The expansile nanoparticle (eNP) in its initial state is 
hydrophobic, but upon endocytosis, transforms to a hydrophilic structure in 
response to endosomal pH less than or equal to 531. Upon this transition, water 
enters and the particle swells and releases the encapsulant (paclitaxel) (Figure 
9). The nanoparticles were prepared from a hydrophobic monomer in which the 
hydroxyl groups of the resulting polymer are masked by an acid-labile protecting 
group. At neutral pH the nanoparticles are stable and do not release the 
encapsulant. A decrease in pH cleaves the protecting group and reveals the 
hydroxyls, causing the desired hydrophobic to hydrophilic transition31. In 2012, 
Khullar et al. demonstrated direct lymphatic migration of eNPs to the regional 
lymph nodes, and colocalization of the encapsulant within the lymph node33. 
They began by injecting dual labeled 50nm and 100nm coumarin conjugated 
eNPs (NIR-C-eNP) encapsulated with IR-813, a NIR fluorescent dye, into the 
hind legs or intestine of pigs. NIR imaging and fluorescent microscopy were used 
to identify intralymphatic migration to the draining mesenteric or inguinal lymph 
nodes33. Nanoparticle-mediated intranodal delivery of chemotherapy was 
additionally assessed with Oregon Green paclitaxel-loaded NIR-eNPs.  
 
Figure 9. eNP expansion characteristics. A) Scanning electron micrograph of eNPs. B) Swelling 
of the eNP and non-expansile nanoparticle (neNP) as a function of time and pH at 37°C. C). 
Amount of hydrolysis of the protecting group as a function of time and pH at 37°C. Figure 
adapted from reference 31. 
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Fluorescent microscopy showed that IR-813 colocalized with both the NIR-C-
eNP and paclitaxel identified within the subcapsular sinuses of the draining 
lymph nodes (Figure 10)32. The study demonstrated the feasibility of targeted 
chemotherapy delivery to regional lymph nodes using eNPs. 
 
Figure 10. Histologic analysis of SLN after intradermal injection of NIR-C-eNP. a) H&E stain of 
SLN b) NIR fluorescence of IR-813 (red) c) coumarin fluorescence of eNP (green) d) Merged IR-
813 and coumarin images confirming co-localization. Figure adapted from reference 32. 
 
3.  SPECIFIC AIMS 
The overall objective of this project was to identify the lymph nodes at greatest 
risk for harboring metastatic disease in patients with lung cancer, and treat them. 
To accomplish this objective, we looked at the feasibility of NIR imaging to safely 
and reliably detect the SLN (Aim I). Secondly, having demonstrated the ability to 
detect the SLNs, we looked at the feasibility of targeted intralymphatic delivery of 
eNPs to treat these lymph nodes in an in-vivo model of micrometastatic thoracic 
disease (Aim II). 
 
Aim I: Identification of the lymph nodes at greatest risk for harboring metastatic 
disease may help physicians more accurately stage the disease, and in turn 
devise more effective adjuvant therapy strategies. Recent attempts at SLN 
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identification in lung cancer have been unsuccessful. ICG and NIR imaging have 
been successful in identifying the SLN in melanoma and breast cancer. 
Therefore, the focus of Aim I was to test the feasibility of ICG and NIR imaging in 
identifying the SLN in lung cancer. To do this, we gave patients an 
intraparenchymal, peritumoral injection of ICG and imaged them with an NIR 
imaging platform. Following imaging, a lymphadenectomy was performed to 
evaluate the regional lymph node basin. 
 
Aim II: Having demonstrated the ability to safely and reliably detect the SLN, we 
wanted to look at the possibility of treating these high risk lymph nodes. Recent 
studies have demonstrated the significance of intralymphatic delivery of drug to 
the lymph node. eNPs have been shown to migrate through the lymphatics of the 
intestine to the SLN in a large animal model. Therefore, the focus of Aim II was to 
demonstrate the intralymphatic delivery of eNPs to the SLN in an in-vivo model of 
micrometastatic disease of the thoracic cavity. To do this, we injected rhodamine 
labeled eNPs into the chest cavity of tumor burdened athymic mice to see if the 
eNPs travel through the lymphatics to the mediastinal lymph nodes. 
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4.  METHODS 
 
4.1  Preparation of ICG solution 
Using sterile technique, a 25mg (32 µmol) vial of ICG, purchased from Novadaq 
Technologies Inc., was diluted in 10mL of normal saline at room temperature 
resulting in a 3.2 mM stock solution. The ICG solution was then diluted in the 
appropriate amount of human serum albumin (HSA)(Flexbumin 25% HSA 
obtained from the Brigham and Women’s Hospital (BWH) Investigational Drug 
Services (IDS) pharmacy) such that the final volume needed to administer the 
appropriate dose per Table 2 was 0.5mL to 2.0mL. Final solutions were prepared 
to a maximum ICG dose of 3.8µg to 2.5mg. The study was conducted as a dose 
escalation to determine safety and the minimum detectable dose (MDD) for SLN 
identification. When an ICG:HSA combination results in 100% SLN identification  
Table 2. Dose Escalation Cohorts 
Group Volume of Injection Total ICG Dose Number of Subjects 
I 
0.5 mL 3.8 µg 4 
1.0 mL 7.75 µg 5 
2.0 mL 15.5 µg 2 
1.0 mL 100 µg 3 
1.0 mL 200 µg 3 
1.0 mL 400 µg 3 
1.0 mL 600 µg 3 
1.0 mL 800 µg 5 
1.0 mL 1000 µg 6 
1.0 mL 2.5 mg 4 
II 1.0 mL MDD (Confirmatory) 4 
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for all subjects in a dosing group, dosing will remain at this level and a 
confirmatory group of subjects will be initiated. 
 
4.2  ICG injection and NIR imaging 
Prior to participating in the study, all patients gave informed consent and met all 
inclusion criteria. The patient had to be at least 18 years of age, have known or 
suspected NSCLC, a single pulmonary nodule of any size, and was planning to 
undergo video assisted thoracic surgery (VATS) or a thoracotomy for 
segmentectomy, lobectomy, bilobectomy, or pneumonectomy. Exclusion criteria 
included pregnancy, lactation, and allergy to iodine, shellfish or ICG. A total of 46 
patients were consented to participate in the study from February 2009 to 
February 2013, however eight failed to meet eligibility criteria or withdrew 
consent prior to the procedure. A dose escalation was performed over the range 
of 3.8µg to 2.5mg. Figure 11 demonstrates the overall schema of the clinical trial. 
After the induction of anesthesia, the surgeon began with the planned resection 
of the tumor by VATS or by thoracotomy. After locating the primary tumor, the 
appropriate volume and dose of ICG described per Table 2 was delivered 
through four injection sites around the tumor into the parenchyma of the lung 
using a 25 gauge needle. Following the injection, the lung was briefly inflated to 
aid lymphatic flow and increase the entry of the ICG solution into the lymphatics. 
After the lung was deflated, the surgical field was imaged for approximately 20 
minutes with a 10mm thoracoscopic SpyScope camera (Novadaq Technologies  
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Inc.) to look for lymphatic drainage within the lung and to identify NIR positive 
lymph nodes (i.e. the SLN). Lymphatic migration, time to SLN identification, 
number of SLNs, and lymph node station were all recorded. The surgeon then 
continued with the lymph node dissection, noting all NIR positive nodes. 
Following imaging, the surgeon proceeded with the planned resection of the 
primary tumor and associated lymphadenectomy. All specimens removed were 
imaged ex-vivo using the NIR camera. Following excision of the primary tumor 
and lymph nodes, the resection site was imaged to ensure all NIR positive nodes 
Figure 11: Flow chart demonstrating clinical trial 05-219 protocol schema. 
Known Disease Unknown Disease 
VATS or Thoracotomy to 
asses mass 
VATS/Thoracotomy 
ICG solution injection ICG solution injection 
1-10 minutes 
Biopsy/Resection of 
mass for diagnosis 
1-10 minutes 
Benign Disease Lung Cancer Disease 
Off study, no SLN harvest 
Surgeon care decision: 
1. No surgery 
2. Surgery via VATS 
SLN Identification 
Planned Resection 
1. Segmentectomy 
2. Lobectomy 
3. Pneumonectomy 
-ID 
+ID 
Lymphadenectomy 
(Image specimen) 
Lymphadenectomy with 
Path/IHC analysis on SLN 
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had been removed. All specimens were then sent for routine pathologic analysis. 
SLNs were divided into three thirds. The first third was sent to surgical pathology 
for routine histologic analysis to ensure the results were available for clinical use. 
The second third was given in formalin to a secondary pathologist for further IHC 
analysis to detect micrometastases, which are defined by the protocol as tumor 
aggregates of 0.2mm to 2.0mm in size and isolated tumor cells or clusters as 
those aggregates measuring <0.2mm12. Given previous analyses and lung tumor 
specificity, analysis with AE1/AE3 cytokeratin antibody, cytokeratins, CK7, and 
thyroid transcription factor-1 were utilized12. The remaining third was submitted to 
the BWH Tissue and Blood Repository to be frozen/stored for future molecular 
studies.  
 
4.3  Expansile Nanoparticle Preparation 
Rhodamine labeled fluorescent eNPs (Rho-eNP) were prepared using a 
miniemulsion polymerization technique which combines high-energy 
emulsification and free radical polymerization of an acrylate monomer. The 
monomer used to design the eNPs possesses a hydrophobic 2,4,6-
trimethoxybenzaldehyde protecting group which is stable at neutral pH but 
hydrolyzes at a slightly acidic pH (~5). Upon exposure to the slightly acidic 
environment of the endosome, the protecting group is cleaved and exposes the 
hydrophilic hydroxyl groups. During polymerization, 0.01% (w/w) 
methacryloxyethyl thiocarbamoyl rhodamine B (Polysciences, Inc., Warrington, 
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PA) was incorporated into the polymer backbone32. The end result was a 
nanoparticle approximately 100nm in diameter that autofluoresces under 
ultraviolet (UV) light.  
 
4.4  In-Vivo Tumor Establishment 
Female athymic nude (Nu/J) mice, purchased from Jackson Laboratory (Bar 
Harbor, ME), were housed under sterile conditions at the Dana Farber Cancer 
Institute Animal Research Facility. Animal care and procedures were conducted 
under strict compliance of all federal and institutional guidelines for the use and 
care of laboratory animals. Four Nu/J mice received an injection of human 
malignant pleural mesothelioma cell line MSTO-211 into the chest cavity. The 
tumor was allowed to grow for approximately 14 days before the animals were 
sacrificed.  
 
4.5  In-Vivo Nanoparticle Lymph Node Migration 
Approximately 3 days prior to sacrifice, the Nu/J mice received an injection of 
Rho-eNPs into the chest cavity. After sacrificing the animals, the chest cavity was 
opened and analyzed under UV light to establish location and show migration of 
the Rho-eNPs. Following UV analysis, a lymphadenectomy was preformed, 
removing the mediastinal and axillary lymph nodes. Along with a sample of lung 
tissue, the lymph nodes were set in Tissue-Tek OCT Compound (Sakura Finetek 
Europe B.V.) and flash frozen in liquid nitrogen. The tissue samples were then 
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sent to pathology to be sliced for histologic analysis. Once sliced, the specimens 
were imaged using confocal imaging to evaluate localization of Rho-eNPs within 
the lymph nodes. 
 
5.  RESULTS 
 
5.1  Patient demographics 
A total of 38 patients underwent peritumoral injection of ICG. 25 female and 13 
male patients participated in the trial. The average age was 64.9 ± 10.3 years. 
We looked at lung cancers in all the different anatomical sites. The largest 
proportion of tumors were located in the left and right upper lobes (LUL, RUL), 
the majority being removed by either wedge resection or lobectomy, as shown in 
Figure 12.  Nearly 89% of the patients (32/38) demonstrated tumor pathology of 
NSCLC, i.e. squamos cell carcinoma, adenocarcinoma, or large cell carcinoma. 
Adenocarcinoma represented the most common tumor pathology, as 
demonstrated in Figure 13. 
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Figure 12. Procedures performed. A total of 38 patients underwent resection for suspected 
NSCLC, with a majority of tumors located in the right and left upper lobes removed by wedge 
resection or lobectomy. 
 
 
Figure 13. Tumor Pathology. 32 patients were found to have NSCLC (adenocarcinoma, squamos 
cell carcinoma, large cell carcinoma), with adenocarcinoma representing the greatest proportion. 
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5.2  ICG dose escalation 
The early ICG dose cohorts (3.8µg-400µg) revealed an overall SLN identification 
rate of 20%, as only 6 SLNs were identified in 4 out of 20 patients. Each 
successive cohort had improved SLN identification rates as displayed in Figure 
14. The 600µg cohort had an identification rate of 33% as 2 SLNs were identified 
in 1 out of 3 patients. The 800µg cohort had an identification rate of 50% as 3 
SLNs were identified in 2 out of 4 patients. The 1.0mg cohort had an 
identification rate of 80% as 6 SLNs were identified in 4 out of 5 patients. The 
2.5mg cohort identified a total of 9 SLNs in 4 out of 4 patients, thus marking the 
MDD for 100% SLN identification. 
 
Figure 14. SLN identification by ICG dose. The percent of SLN identification increased with each 
successive ICG dose cohort, reaching 100% SLN identification in the 2.5mg cohort. 
 
5.3  SLN stations 
ICG and NIR imaging identified a total of 26 SLNs in 15 patients, confirmed by 
ex-vivo imaging of the lymph nodes (Figure 15). The SLNs were identified across 
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6 different stations, ranging from N1 nodes (stations 10-14) to N2 nodes (stations 
1-9) (Figure 16). 19 SLNs were identified as N1 nodes, 14 in station 10 and 5 in 
station 11. The remaining 7 SLNs were identified as N2 nodes, 2 in station 9, 1 in 
station 5 and 4 in station 4.  
 
Figure 15. Ex-vivo SLN confirmation. All lymph nodes specimens removed during the 
lyphadenectomy were imaged ex-vivo to confirm NIR status. 
 
 
Figure 16. SLN identification by lung location and station. The greatest proportion of SLNs were 
identified in the right and left upper lobes, in the station 10 position.  
 35 
5.4  NIR mediated SLN identification in detection of metastatic nodal disease 
A total of 6 patients were found to have metastatic disease within the sampled 
lymph nodes out of the 15 patients with a positive SLN identification. Metastatic 
disease was found within at least 1 SLN in each patient (7 SLNs in 6 patients), 
demonstrating the significance of the SLN in the progression of metastatic 
disease. 
 
5.5  Rho-eNP migration 
Four Nu/J mice received an intrathoracic injection of MSTO-211 tumor cells 14 
days prior to sacrifice. Each mouse received an additional intrathoracic injection 
of Rho-eNPs 3 days prior to sacrifice. After being sacrificed, 3 out of 4 mice were 
analyzed under UV light for Rho-eNP migration. The fourth mouse did not 
undergo UV analysis due to the high tumor burden obscuring the ability to locate 
the mediastinal lymph node. Upon opening the chest cavity, UV inspection 
revealed Rho-eNP migration as a fluorescent orange color concentrated near the 
mediastinal lymph node in 100% (3 out of 3) of the analyzed animals. Additional 
histologic analysis will be needed to confirm the mediastinal lymph node samples 
are in fact lymph nodes. Future confocal imaging can confirm the localization of 
the Rho-eNPs within the mediastinal lymph nodes. 
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6.  DISCUSSION 
Lung cancer is the leading cause of all cancer deaths in men and women 
combined, killing more than 150,000 patients per year. Lymph node status is the 
best predictor of survival in patients with surgically resectable lung cancer. 
However, there lacks a safe and reliable method for identifying the lymph nodes 
at greatest risk for harboring metastatic disease, i.e. SLNs. Understaging of the 
disease leads to undertreatment and in turn, a greater chance for recurrence. 
The overall objective of this project was to identify the high risk lymph nodes and 
treat them. 
 
Aim I of this project was to look at a new imaging technology to identify the SLN 
in lung cancer. Previous studies using radioisotopes and blue dyes produced 
unreliable and inconsistent results with low sensitivity and specificity, with SLN 
identification rates ranging from 6 - 82%. Our results demonstrated the ability of 
ICG and NIR imaging to safely and reliably detect the SLN in a minimally 
invasive VATS procedure. The ICG dose cohort of 2.5mg had a 100% SLN 
identification rate. Additionally, in patients who had metastatic disease, it was 
found in the SLN identified by ICG and NIR imaging. This further demonstrates 
the ability of ICG and NIR imaging to identify the lymph nodes at greatest risk for 
harboring metastatic disease. 
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Given this success, we next looked to treat these high risk lymph nodes. In 2004, 
Chen et al. demonstrated that lymphatic delivery of chemotherapy is an effective 
strategy for increasing the drug concentration in the regional lymph nodes. In 
2012, Khullar et al. demonstrated the intralymphatic delivery of paclitaxel loaded 
eNPs to tumor cells in the intestine of a large animal. The objective of aim II was 
to extend these observations to thoracic malignancies. Our UV analysis results 
demonstrated there was some sort of lymphatic migration of the Rho-eNPs within 
the chest cavity of the mice. Based on these results, it can be inferred that an 
injection of eNPs into the lung would flow through the lymph system to the lymph 
nodes. This in turn opens up treatment options for physicians. Direct injection of 
paclitaxel loaded eNPs into the lung would allow for greater doses of 
chemotherapy to safely be delivered to the high risk lymph nodes, increasing the 
concentration of the drug within the lymph nodes while avoiding systemic toxicity. 
Future studies would require demonstrating the lymphatic migration of eNPs 
within the lung in a large animal model, with a lymphatic drainage pattern similar 
to that of humans. Positive results in this experiment would suggest successful 
migration of eNPs to the SLN in human lungs, thereby expanding the therapy 
options for patients with lung cancer. 
 
ICG and NIR imaging have demonstrated to be a safe, reliable and effective 
method for SLN identification. Combined with targeted lymphatic drug delivery by 
eNPs loaded with chemotherapy, the results have demonstrated the feasibility of 
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treating and preventing the metastatic spread of disease without invasive 
surgery. The targeted delivery of paclitaxel loaded eNPs to the NIR identified 
SLNs may help to prevent recurrent disease, thereby increasing 5 year survival 
rates and reducing mortality rates for patients with lung cancer. 
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